Currently Viewing:
Currently Reading
FDA Issues Alert About Fluid-Filled Balloons to Treat Obesity
February 14, 2017 – AJMC Staff
What We're Reading: DMD Drug Gets $89K Price Tag; Necessary Drug Price Hikes; and ACA Taxes
February 13, 2017 – AJMC Staff
Low Socioeconomic Status Linked to Reduced Life Expectancy
February 12, 2017 – Laura Joszt
Self-Management Interventions Could Improve Outcomes for Low-Income Diabetics
February 10, 2017 – Christina Mattina
This Week in Managed Care: February 10, 2017
February 10, 2017
The Complex Relation Between Clinical Outcomes, Drug Approval, and Drug Price
February 10, 2017 – Surabhi Dangi-Garimella, PhD
Air Pollution Tied to Increased Type 2 Diabetes Risk in Latino Children
February 09, 2017 – Mary Caffrey
Michigan Study Finds Obesity Lowers Hospice Use Among Seniors
February 08, 2017 – Surabhi Dangi-Garimella, PhD
Gastric Bypass Reversal: Diabetes Can Return, Even if Weight Doesn't
February 08, 2017 – Mary Caffrey

FDA Issues Alert About Fluid-Filled Balloons to Treat Obesity

AJMC Staff
So far, the adverse events have been reported for the 2 fluid-filled designs, not for an air-filed design later approved.
The FDA has alerted healthcare providers about reports of adverse events from the fluid-filled balloons approved over the past 2 years to treat obesity.

The FDA’s February 9, 2016, notice reports 2 types of events:

  • The balloons overinflate with air or more fluid, requiring early removal.
  • Patients develop acute pancreatitis, although how this occurs is unknown.

In 2015, the FDA approved 2 fluid-filled balloon systems, the ReShape integrated dual balloon system, and the Orbera balloon system. ReShape uses 2 balloons, while Orbera uses 1 balloon. Both systems place the balloons into the stomach through the mouth, using an endoscopic procedure.

In 2016, the FDA has also approved the Obalon system, which uses a swallowable capsule to place up to 3 balloons. The capsule is attached to a catheter used to fill the balloons with air. So far, the FDA, reports, the adverse events reported have not affected this balloon system.

The FDA reminds providers to report any adverse reactions through its MedWatch system, which can be found here.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up